I agree that this site is using cookies. You can find further informations here.
X
Leleu, X
312  results:
Search for persons X
?
1

French early nationwide idecabtagene vicleucel chimeric ant..:

Ferment, B. ; Lambert, J. ; Caillot, D....
British Journal of Haematology.  , 2024
Link: https://doi.org/10.1111/..
 
?
2

P33 EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN PAT..:

Roussel, M. ; Texier, N. ; Germain, R....
HemaSphere.  7 (2023)  S2 - p. 29-29 , 2023
Link: https://doi.org/10.1097/..
 
?
3

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) ..:

Weisel, K. ; Kumar, S. ; Moreau, P....
HemaSphere.  7 (2023)  S2 - p. 14-15 , 2023
Link: https://doi.org/10.1097/..
 
?
4

EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSE..:

Nooka, A ; Lesokhin, A ; Mohty, M...
Hematology, Transfusion and Cell Therapy.  45 (2023)  - p. S405 , 2023
Link: https://doi.org/10.1016/..
 
?
5

Real-world effectiveness of ixazomib combined with lenalido..:

Macro, M. ; Hulin, C. ; Vincent, L....
Annals of Hematology.  102 (2023)  8 - p. 2137-2151 , 2023
Link: https://doi.org/10.1007/..
 
?
6

EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PA..:

Raje, N ; Leleu, X ; Lesokhin, A...
Hematology, Transfusion and Cell Therapy.  45 (2023)  - p. S406-S407 , 2023
Link: https://doi.org/10.1016/..
 
?
7

P25 Association between Adherence to Lenalidomide and Patie..:

Ramasamy, K. ; von Lilienfeld-Toal, M. ; Maisel, C....
Value in Health.  26 (2023)  12 - p. S6-S7 , 2023
Link: https://doi.org/10.1016/..
 
?
8

P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A L..:

Schavgoulidze, A. ; Perrot, A. ; Cazaubiel, T....
HemaSphere.  6 (2022)  - p. 765-766 , 2022
Link: https://doi.org/10.1097/..
 
?
9

P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-R..:

Facon, T. ; Kumar, S. K. ; Plesner, T....
HemaSphere.  6 (2022)  - p. 826-827 , 2022
Link: https://doi.org/10.1097/..
 
?
10

P956: EMMY COHORT: MANAGEMENT OF NEWLY DIAGNOSED OR RELAPSE..:

Macro, M. ; Decaux, O. ; Perrot, A....
HemaSphere.  6 (2022)  - p. 846-847 , 2022
Link: https://doi.org/10.1097/..
 
?
11

P24: EXPERT PERSPECTIVES OF UNMET NEED IN PATIENTS WITH REL..:

Mateos, M ; Leleu, X ; Zamagni, E...
HemaSphere.  6 (2022)  - p. 24-25 , 2022
Link: https://doi.org/10.1097/..
 
?
12

P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DAR..:

Macro, M. ; Touzeau, C. ; Mariette, C....
HemaSphere.  6 (2022)  - p. 819-820 , 2022
Link: https://doi.org/10.1097/..
 
?
13

P925: IMPACT OF PRIOR TREATMENT EXPOSURE ON THE EFFECTIVENE..:

Lee, H. C. ; Ramasamy, K. ; Macro, M....
HemaSphere.  6 (2022)  - p. 815-816 , 2022
Link: https://doi.org/10.1097/..
 
?
14

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS ..:

Quach, H. ; Leleu, X. ; Mateos, M.-V....
HemaSphere.  6 (2022)  - p. 798-799 , 2022
Link: https://doi.org/10.1097/..
 
?
15

P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS S..:

Usmani, S ; Alonso, A ; Quach, H...
HemaSphere.  6 (2022)  - p. 19-19 , 2022
Link: https://doi.org/10.1097/..
 
1-15